Owl Therapeutics Inks Clinical Pact with Abliva To Advance NeuroSTAT

Owl Therapeutics, a fully owned subsidiary of Gryphon Bio, announced a global license and partnership agreement with Lund, Sweden-based Abliva AB to advance Abliva's NeuroSTAT (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI). TBI is an urgent and prominent public health challenge, impacting millions each year as a result of head trauma from accidents, falls, sports-related incidents, and military combat. TBI disrupts the normal functioning of the brain, leading to a range of cognitive, physical, and emotional symptoms, as per pharmabiz. "Abliva stands out as an exceptional partner for Owl Therapeutics, and we are excited to join forces in our collective commitment to advance NeuroSTAT (OWL-1410)," said William E. Haskins, Ph.D., co-founder of Owl Therapeutics and chief executive officer of Gryphon Bio.

"We are thrilled to focus our team's scientific, clinical, and business experience on this potentially game-changing treatment for military and civilian TBI patients." Under the terms of the agreement, Abliva will contribute to both the operational and strategic elements of the program through the established steering committee.

Owl Therapeutics will lead the clinical development and commercialization of NeuroSTAT. Upon commercialization, Abliva is eligible for royalties. As per the provisions of the agreement, Abliva will contribute to the program's operational and strategic features through the created steering committee. Owl Therapeutics will be in charge of NeuroSTAT's clinical development and commercialization.

Abliva is eligible for royalties upon commercialization. "Through this important collaboration with Abliva, Owl Therapeutics gains access to an innovative asset for TBI with orphan drug designation (ODD) in Europe and the US, as well as an investigational new drug (IND) approval granted Fast Track designation for clinical development and review in the US," said Franklin Okumu, PhD, and chief technology officer of Owl Therapeutics. "We are also excited by the potential to collaborate with clinical investigators to rapidly advance this treatment to patients in need."